| Name | Title | Contact Details |
|---|
Founded in 1947 in Milan, Italy RUPES has been an producer of innovative specialty tools for over 70 years. RUPES USA is the North American arm of the Italian based tool manufacturer located in Louisville, Colorado. This location operates as the headquarters for all North American based activities including management, sales, customer support, repair, and manufacturing. In addition to the administrative and business functions of the US headquarters the Colorado location also houses a state of the art training and education facility known as the BigFoot Academy where technicians from a variety of industries can come for industry leading training in a number of disciplines centered on sanding and polishing operations. Visitors to our facility are welcome by appointment only, but we encourage you to contact our US offices via email at info@rupesusa.com to schedule a visit or on-site tour of our new home.
At Diversity Matters, we support businesses that encourage diversity. With our consulting services we aim to help businesses understand the power of inclusion. Whether youre just starting to embrace diversity in your organization or looking to strengthen existing initiatives, Diversity Matters can help.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
IQUW is a global specialty (re) insurer at Lloyds (syndicate 1856), underwriting complex risks and developing a new way to combine data, intelligent automation and human expertise to make smart decisions, fast. Led by a team of expert underwriters, we underwrite a diverse, multi-line product portfolio including Cargo, Cyber, Delegated Authority Property, D&F Property, D&O, Energy, Financial Institutions, Marine and Energy Liability, Political Violence, Terrorism and War, Property Treaty and Specialty Reinsurance. And because we are a Lloyds syndicate, all our policies come with an A+ rating from Lloyds. To connect with a member of the IQUW team, visit IQUW.com or to visit, you can find us at our HQ in 30 Fenchurch Street, London or at Box 64, 137 and 221 at Lloyds.